B7-H3 molecular imaging for the era of pan-cancer targeted therapy.
- 1Department of Occupational Pulmonology, Shandong First Medical University Affiliated Occupational Disease Hospital (Shandong Occupational Disease Hospital), Jinan, Shandong, China.
- 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Abstract
B7-H3 (CD276) is broadly overexpressed across solid tumors and plays active roles in immune evasion, tumor angiogenesis, and metabolic reprogramming. As B7-H3-directed antibody-drug conjugates chimeric antigen receptor T-cell therapies, and radioimmunotherapy agents advance through clinical trials, non-invasive whole-body imaging of B7-H3 expression has become a pressing clinical need. Tissue biopsy with IHC cannot capture systemic target heterogeneity, and the recent IDeate-PanTumor01 trial found no correlation between baseline B7-H3 H-score and response to ifinatamab deruxtecan-illustrating the gap that molecular imaging must fill. This mini review surveys B7-H3-targeted imaging agents by scaffold class-antibodies, affibodies, nanobodies, and bicyclic peptides-and examines radioimmunotherapy platforms that couple PET-based dosimetry with targeted radionuclide delivery.
Related
- Quantitative Molecular Breast Imaging for Early Prediction of Neoadjuvant Systemic Therapy Response in Locally Advanced Breast Cancer Patients
- Precision Oncology: Cancer Specialists’ Perspectives on Molecular Profiling, Targeted Therapy, and Barriers to Access
- Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy
- Periprocedural Wound Complication Risks in Cancer Pain Patients Following Targeted Cancer Therapy: A Retrospective Analysis
- Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies
BibTeX
@article{liu2026b7h3,
title = {{B7-H3 molecular imaging for the era of pan-cancer targeted therapy.}},
author = {Baoyan Liu and Kelin Wang and Kewen He and Yong Wang},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1923470},
url = {https://europepmc.org/article/MED/42903186},
note = {CC BY},
}
RIS
TY - JOUR
TI - B7-H3 molecular imaging for the era of pan-cancer targeted therapy.
AU - Baoyan Liu
AU - Kelin Wang
AU - Kewen He
AU - Yong Wang
PY - 2026
DA - 2026/10/06
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1923470
UR - https://europepmc.org/article/MED/42903186
AB - B7-H3 (CD276) is broadly overexpressed across solid tumors and plays active roles in immune evasion, tumor angiogenesis, and metabolic reprogramming. As B7-H3-directed antibody-drug conjugates chimeric antigen receptor T-cell therapies, and radioimmunotherapy agents advance through clinical trials, non-invasive whole-body imaging of B7-H3 expression has become a pressing clinical need. Tissue biopsy with IHC cannot capture systemic target heterogeneity, and the recent IDeate-PanTumor01 trial found no correlation between baseline B7-H3 H-score and response to ifinatamab deruxtecan-illustrating the gap that molecular imaging must fill. This mini review surveys B7-H3-targeted imaging agents by scaffold class-antibodies, affibodies, nanobodies, and bicyclic peptides-and examines radioimmunotherapy platforms that couple PET-based dosimetry with targeted radionuclide delivery.
SN - 1663-9812
ER -